Loading...

Celyad

ENXTBR:CYAD
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CYAD
ENXTBR
€211M
Market Cap
  1. Home
  2. BE
  3. Pharmaceuticals & Biotech
Company description

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of hematological malignancies and solid tumors. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
CYAD Share Price and Events
7 Day Returns
1.6%
ENXTBR:CYAD
0.8%
BE Biotechs
-1.1%
BE Market
1 Year Returns
-27.7%
ENXTBR:CYAD
24.2%
BE Biotechs
-9.4%
BE Market
CYAD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Celyad (CYAD) 1.6% -3.8% -1.1% -27.7% -61.5% -51.9%
BE Biotechs 0.8% 7% 5.1% 24.2% 207.2% 50.6%
BE Market -1.1% -7.2% 4.2% -9.4% -17.2% 2%
1 Year Return vs Industry and Market
  • CYAD underperformed the Biotechs industry which returned 24.2% over the past year.
  • CYAD underperformed the Market in Belgium which returned -9.4% over the past year.
Price Volatility
CYAD
Industry
5yr Volatility vs Market

CYAD Value

 Is Celyad undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Celyad. This is due to cash flow or dividend data being unavailable. The share price is €17.7.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Celyad's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Celyad's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTBR:CYAD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-3.36
ENXTBR:CYAD Share Price ** ENXTBR (2019-05-23) in EUR €17.7
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 21.59x
Belgium Market PE Ratio Median Figure of 86 Publicly-Listed Companies 14.93x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Celyad.

ENXTBR:CYAD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:CYAD Share Price ÷ EPS (both in EUR)

= 17.7 ÷ -3.36

-5.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celyad is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Celyad is loss making, we can't compare the value of its earnings to the Belgium market.
Price based on expected Growth
Does Celyad's expected growth come at a high price?
Raw Data
ENXTBR:CYAD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
2.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.27x
Belgium Market PEG Ratio Median Figure of 41 Publicly-Listed Companies 1.87x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Celyad, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Celyad's assets?
Raw Data
ENXTBR:CYAD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €4.65
ENXTBR:CYAD Share Price * ENXTBR (2019-05-23) in EUR €17.7
Belgium Biotechs Industry PB Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 2.94x
Belgium Market PB Ratio Median Figure of 120 Publicly-Listed Companies 1.55x
ENXTBR:CYAD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:CYAD Share Price ÷ Book Value per Share (both in EUR)

= 17.7 ÷ 4.65

3.8x

* Primary Listing of Celyad.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celyad is overvalued based on assets compared to the BE Biotechs industry average.
X
Value checks
We assess Celyad's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Celyad has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CYAD Future Performance

 How is Celyad expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Celyad expected to grow at an attractive rate?
  • Celyad's earnings growth is expected to exceed the low risk savings rate of 0.8%.
Growth vs Market Checks
  • Celyad's earnings growth is positive but not above the Belgium market average.
  • Celyad's revenue growth is expected to exceed the Belgium market average.
Annual Growth Rates Comparison
Raw Data
ENXTBR:CYAD Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTBR:CYAD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 2.7%
ENXTBR:CYAD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 49.8%
Belgium Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 51.3%
Belgium Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 46.7%
Belgium Market Earnings Growth Rate Market Cap Weighted Average 9.4%
Belgium Market Revenue Growth Rate Market Cap Weighted Average 3.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTBR:CYAD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTBR:CYAD Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 199 5 1
2022-12-31 22 -19 1
2021-12-31 70 -54 -56 4
2020-12-31 4 -45 -49 8
2019-12-31 4 -37 -39 6
ENXTBR:CYAD Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -27 -37
2018-09-30 3 -49
2018-06-30 3 -44 -60
2018-03-31 3 -44 -58
2017-12-31 4 -44 -56
2017-09-30 9 -39
2017-06-30 12 -18 -21
2017-03-31 10 -22 -22
2016-12-31 10 -25 -24
2016-09-30 4 -31 -27
2016-06-30 0 -38 -31
2016-03-31 0 -32 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Celyad's earnings are expected to grow by 2.7% yearly, however this is not considered high growth (20% yearly).
  • Celyad's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTBR:CYAD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Celyad Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTBR:CYAD Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -3.38 -3.38 -3.38 1.00
2020-12-31 -5.69 -3.38 -8.00 2.00
2019-12-31 -3.93 -2.67 -6.00 3.00
ENXTBR:CYAD Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -3.36
2018-09-30 -4.62
2018-06-30 -6.01
2018-03-31 -5.94
2017-12-31 -5.86
2017-09-30 -4.07
2017-06-30 -2.24
2017-03-31 -2.39
2016-12-31 -2.53
2016-09-30 -2.89
2016-06-30 -3.24
2016-03-31 -3.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Celyad will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Celyad's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Belgium market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Belgium market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Celyad has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CYAD Past Performance

  How has Celyad performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Celyad's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Celyad does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Celyad's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Celyad's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Celyad's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Celyad Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTBR:CYAD Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.12 -37.43 10.39 23.58
2018-09-30 2.83 -48.93 10.46 23.24
2018-06-30 2.55 -60.44 10.52 22.90
2018-03-31 3.05 -58.42 9.92 22.90
2017-12-31 3.54 -56.40 9.31 22.91
2017-09-30 9.25 -38.75 9.28 23.14
2017-06-30 11.99 -21.10 9.25 23.38
2017-03-31 10.26 -22.35 9.50 25.53
2016-12-31 10.01 -23.61 9.74 27.68
2016-09-30 4.28 -27.15 9.04 27.17
2016-06-30 0.04 -30.70 8.34 26.67
2016-03-31 0.02 -29.91 7.79 24.72
2015-12-31 0.00 -29.11 7.23 22.77
2015-09-30 0.07 -27.26 6.93 21.82
2015-06-30 0.15 -25.41 6.62 20.88
2015-03-31 0.15 -20.93 5.82 18.37
2014-12-31 0.15 -16.45 5.02 15.87
2014-09-30 0.07 -15.45 5.06 15.18
2014-06-30 -14.44 5.10 14.49
2014-03-31 -14.95 4.51 11.77
2013-12-31 -14.49 3.97 9.05
2013-09-30 0.03 -12.77 2.38 2.28
2013-06-30 0.05 -13.20 1.77 2.41
2013-03-31 0.05 -11.90 1.85 2.69
2012-12-31 0.05 -13.52 1.88 3.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Celyad has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Celyad has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Celyad improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Celyad's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Celyad has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CYAD Health

 How is Celyad's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Celyad's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Celyad is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Celyad's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Celyad's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 31.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Celyad Company Filings, last reported 4 months ago.

ENXTBR:CYAD Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 55.59 1.65 49.74
2018-09-30 55.59 1.65 49.74
2018-06-30 72.68 1.30 63.23
2018-03-31 72.68 1.30 63.23
2017-12-31 47.54 1.44 33.91
2017-09-30 47.54 1.44 33.91
2017-06-30 77.25 1.20 68.84
2017-03-31 77.25 1.20 68.84
2016-12-31 90.89 1.48 82.59
2016-09-30 90.89 1.48 82.59
2016-06-30 96.63 1.74 86.03
2016-03-31 96.63 1.74 86.03
2015-12-31 111.47 0.68 107.51
2015-09-30 111.47 0.68 107.51
2015-06-30 124.89 0.50 123.79
2015-03-31 124.89 0.50 123.79
2014-12-31 26.68 0.41 30.30
2014-09-30 26.68 0.41 30.30
2014-06-30 35.68 0.32 40.07
2014-03-31 35.68 0.32 40.07
2013-12-31 16.90 0.11 22.06
2013-09-30 16.90 0.11 22.06
2013-06-30 -1.12 0.17 3.94
2013-03-31 -4.44 0.22 0.11
2012-12-31 -2.26 0.27 1.65
  • Celyad's level of debt (3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.6% vs 3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Celyad has sufficient cash runway for 1.7 years based on current free cash flow.
  • Celyad has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 7.4% each year.
X
Financial health checks
We assess Celyad's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Celyad has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CYAD Dividends

 What is Celyad's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Celyad dividends. Estimated to be 0% next year.
If you bought €2,000 of Celyad shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Celyad's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Celyad's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTBR:CYAD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Belgium Market Average Dividend Yield Market Cap Weighted Average of 78 Stocks 3.7%
Belgium Minimum Threshold Dividend Yield 10th Percentile 1.2%
Belgium Bottom 25% Dividend Yield 25th Percentile 2.5%
Belgium Top 25% Dividend Yield 75th Percentile 4.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTBR:CYAD Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Celyad has not reported any payouts.
  • Unable to verify if Celyad's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Celyad's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Celyad has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Celyad's dividends in 3 years as they are not expected to pay a notable one for Belgium.
X
Income/ dividend checks
We assess Celyad's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Celyad afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Celyad has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CYAD Management

 What is the CEO of Celyad's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Filippo Petti
AGE 46
TENURE AS CEO 0.1 years
CEO Bio

Mr. Filippo Joseph Petti has been the Chief Executive Officer and Chief Financial Officer of Celyad SA since April 1, 2019. Mr. Petti served as the Chief Financial Officer at Celyad SA since September 2018 until April 1, 2019. Mr. Petti served as Chief Financial Officer and Investor Relations at Celyad SA since September 03, 2018 until September 2018. He currently serves as vice president of healthcare investment banking at Wells Fargo Securities. Before joining Wells Fargo Securities, he was vice president of healthcare investment banking at William Blair & Company. Prior to his roles in investment banking, Mr. Petti worked in equity research both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. before transitioning to corporate development with the company. Mr. Petti holds a Master of Business Administration from Cornell University, a Master of Science from St. John’s University and a Bachelor of Science from Syracuse University.

CEO Compensation
  • Insufficient data for Filippo to compare compensation growth.
  • Insufficient data for Filippo to establish whether their remuneration is reasonable compared to companies of similar size in Belgium.
Management Team Tenure

Average tenure and age of the Celyad management team in years:

2.3
Average Tenure
48
Average Age
  • The tenure for the Celyad management team is about average.
Management Team

Michel Lussier

TITLE
Co-Founder & Chairman
COMPENSATION
€86K
AGE
62

Filippo Petti

TITLE
CEO & CFO
AGE
46
TENURE
0.1 yrs

Jean-Pierre Latere

TITLE
Chief Operating Officer
AGE
43
TENURE
2.3 yrs

Nicolas Van Hoecke

TITLE
Director of Investor Relations & Communications
TENURE
0.7 yrs

Philippe Dechamps

TITLE
Chief Legal Officer
AGE
48
TENURE
2.7 yrs

Philippe Nobels

TITLE
Global Head of Human Resources
AGE
52
TENURE
2.6 yrs
Board of Directors Tenure

Average tenure and age of the Celyad board of directors in years:

7.5
Average Tenure
58.5
Average Age
  • The tenure for the Celyad board of directors is about average.
Board of Directors

Michel Lussier

TITLE
Co-Founder & Chairman
COMPENSATION
€86K
AGE
62
TENURE
12.3 yrs

Christian Homsy

TITLE
Director
COMPENSATION
€477K
AGE
60
TENURE
12.3 yrs

Serge Goblet

TITLE
Non-Executive Director
COMPENSATION
€36K
AGE
60
TENURE
11.3 yrs

Chris Buyse

TITLE
Independent Director
COMPENSATION
€71K
AGE
54
TENURE
11.3 yrs

Rudy DeKeyser

TITLE
Independent Director
COMPENSATION
€81K
AGE
56
TENURE
12.3 yrs

Debasish Roychowdhury

TITLE
Independent Director
COMPENSATION
€62K
AGE
57
TENURE
3.8 yrs

Hinrich Abken

TITLE
Member of Scientific Advisory Board
TENURE
3.1 yrs

Scott Antonia

TITLE
Member of Scientific Advisory Board
TENURE
3.1 yrs

Marco Davila

TITLE
Member of Scientific Advisory Board
TENURE
3.1 yrs

Marc Ernstoff

TITLE
Member of Scientific Advisory Board
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Celyad's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Celyad has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CYAD News

Simply Wall St News

The Celyad (EBR:CYAD) Share Price Is Down 57% So Some Shareholders Are Wishing They Sold

Given that Celyad didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … In the last three years, Celyad saw its revenue grow by 12% per year, compound.

Simply Wall St -

Do Insiders Own Shares In Celyad SA (EBR:CYAD)?

Celyad is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that. … institutional investors have bought into the company

Simply Wall St -

Should You Worry About Celyad SA's (EBR:CYAD) CEO Pay?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … Check out our latest analysis for Celyad? … How Does Christian Homsy's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Does Celyad SA (EBR:CYAD) Have A Particularly Volatile Share Price?

If you're interested in Celyad SA (EBR:CYAD), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Do Institutions Own Celyad SA (EBR:CYAD) Shares?

The big shareholder groups in Celyad SA (EBR:CYAD) have power over the company. … With a market capitalization of €287m, Celyad is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Celyad

Simply Wall St -

How Celyad SA (EBR:CYAD) Can Impact Your Portfolio Volatility

Generally, an investor should consider two types of risk that impact the market value of CYAD. … The second type is market risk, one that you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks in the market. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one.

Simply Wall St -

When Can We Expect A Profit From Celyad SA (EBR:CYAD)?

The €329.93m market-cap company announced a latest loss of -€56.39m on 31 December 2017 for its most recent financial year result. … I’ve put together a brief outline of industry analyst expectations for CYAD, its year of breakeven and its implied growth rate … See our latest analysis for Celyad

Simply Wall St -

Celyad SA's (EBR:CYAD) Sustainability In Question?

Cash management is still not optimal and should be improved, but its overall debt level and interest coverage somewhat increases my conviction of the sustainability of the business going forward. … CYAD has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like CYAD as a business is its low level of fixed assets on its balance sheet (4.24% of total assets).

Simply Wall St -

What Are Analysts Saying About Celyad SA's (EBR:CYAD) Future?

In December 2017, Celyad SA (ENXTBR:CYAD) released its most recent earnings announcement, which confirmed that losses became smaller relative to the prrior year's level as a result of recent tailwinds Investors may find it useful to understand how market analysts view Celyad's earnings growth trajectory over the next couple of years and whether the future looks brighter. … ENXTBR:CYAD Future Profit Mar 26th 18 Even though it’s useful to understand the growth rate each year relative to today’s value, it may be more beneficial to evaluate the rate at which the earnings are moving every year, on average. … The slope of this line is the rate of earnings growth, which in this case is 32.57%.

Simply Wall St -

CYAD Company Info

Description

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of hematological malignancies and solid tumors. The company’s lead drug product candidate, CYAD-01 (CAR-T-NKG2D), an autologous chimeric antigen receptor that is in Phase I clinical trials, which expresses the NKG2D receptor from natural killer (NK) cells that binds to eight stress-induced ligands expressed on tumor cells for the treatment of patients with relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an investigational, non-gene edited allogeneic CAR-T therapy that is in Phase I trials, which co-expresses the NKG2D receptor of CYAD-01 and the inhibitory peptide Tcell receptor inhibiting molecule; and preclinical development CAR-T product candidates, such as CYAD-02 and CYAD-03 for the treatment of hematological malignancies and solid tumors. In addition, the company’s short hairpin RNA-based allogeneic CAR-T candidates comprise CYAD-211, a B-cell maturation antigen targeting CAR-T candidate for the treatment of multiple myeloma; CYAD-221, a CD19 targeting CAR-T candidate for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Details
Name: Celyad SA
CYAD
Exchange: ENXTBR
Founded: 2004
€211,379,488
11,942,344
Website: http://www.celyad.com
Address: Celyad SA
Axis Business Park,
Rue Edouard Belin 2,
Mont-Saint-Guibert,
Walloon Brabant, 1435,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR CYAD Ordinary Shares Euronext Brussels BE EUR 04. Jul 2013
OTCPK CLYY.F Ordinary Shares Pink Sheets LLC US USD 04. Jul 2013
DB 1C0 Ordinary Shares Deutsche Boerse AG DE EUR 04. Jul 2013
LSE 0QFK Ordinary Shares London Stock Exchange GB EUR 04. Jul 2013
BATS-CHIXE CYADB Ordinary Shares BATS 'Chi-X Europe' GB EUR 04. Jul 2013
NasdaqGM CYAD ADR Nasdaq Global Market US USD 22. Jun 2015
Number of employees
Current staff
Staff numbers
94
Celyad employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 22:01
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/17
Last earnings filing: 2019/04/05
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.